bluebird bio Reports Rapid Transfusion Independence in Beta-Thalassemia Major Patients Treated with its LentiGlobin Product Candidate

First two patients in the HGB-205 Study achieved transfusion independence within two weeks of an autologous transplant with bluebird’s lentiviral gene therapy

CAMBRIDGE, Mass.-- bluebird bio, Inc. (BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today released initial positive clinical data from its HGB-205 clinical study of its LentiGlobin BB305 product candidate in beta-thalassemia major subjects at the 19^th Annual Congress of the European Hematology Association (EHA) in Milan, Italy.

US FDA advisory committee recommends no cardiovascular outcomes trial for peripherally-acting mu-opioid receptor antagonist (pamora) class including movantik

SAN FRANCISCO, June 12, 2014  Nektar Therapeutics (NKTR) reported today that partner AstraZeneca announced that the majority of US Food and Drug Administration (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) members voted that the FDA should not require cardiovascular outcomes trials for the peripherally-acting mu-opioid receptor antagonist (PAMORA) class of drugs, which includes MOVANTIK^TM (naloxegol oxalate), an investigational treatment for opioid-induced constipation (OIC) for patients with chronic non-cancer pain. Following a clarification of the vote, the majority of the Committee suggested continued post-approval data collection for cardiovascular safety.

Provectus Biopharmaceuticals to Discuss Outline of Phase 3 Clinical Trial Of PV-10 To Treat Melanoma on Conference Call

Management Will Also Discuss Access to ASCO-Presented Phase 2 Melanoma Data, Developments in Other Cancer Indications and in PH-10 Use
Call Scheduled for Thursday, June 19, 2014 at 4 pm Eastern Daylight Time

KNOXVILLE, Tenn. -- Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT), (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that it will hold a conference call on Thursday, June 19, 2014, at 4 pm Eastern Daylight Time.

Management will discuss the outline of the Company’s proposed Phase 3 study of PV-10 in the treatment of melanoma, developments in the use of PV-10 in other cancer indications, as well as PH-10 and news regarding its use. Management will also discuss its potential plans to monetize its PV-10 and PH-10 assets with various contemplated license and co-development transactions.